Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MediciNova Plans To License MS Agent To European And U.S. Drugmakers

This article was originally published in PharmAsia News

Executive Summary

MediciNova plans to license MN-166 (ibudilast) to European and U.S. drugmakers within the year after a Phase II trial in April showed promising results. A novel, orally administered compound being evaluated to treat multiple sclerosis, ibudilast was licensed from Kyorin Pharmaceutical and has been marketed under the name Ketas for the treatment of asthma and cerebrovascular disorders for the past 18 years. In case of a licensing agreement, which could be reached as early as the end of the year, MediciNova and Kyorin will share a one time payment and royalty payments at a 65-35 split. MedicNova expects the drug to grow to ¥120 billion in sales in five years. MediciNova will also release Phase II results for MN-221 (ritodrine) by the end of the year. Licensed from Kissei Pharmaceutical, ritodrine is being evaluated by the company as an asthma treatment. (Click here for more - Japanese language
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC067358

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel